Compare HRMY & BAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | BAK |
|---|---|---|
| Founded | 2017 | 1972 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2020 | 2002 |
| Metric | HRMY | BAK |
|---|---|---|
| Price | $27.73 | $4.08 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 2 |
| Target Price | ★ $46.70 | $4.40 |
| AVG Volume (30 Days) | 900.4K | ★ 2.9M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.97 | N/A |
| EPS | ★ 2.71 | N/A |
| Revenue | ★ $868,453,000.00 | N/A |
| Revenue This Year | $19.87 | N/A |
| Revenue Next Year | $12.49 | $5.40 |
| P/E Ratio | $10.22 | ★ N/A |
| Revenue Growth | ★ 21.51 | N/A |
| 52 Week Low | $25.52 | $2.32 |
| 52 Week High | $40.87 | $5.30 |
| Indicator | HRMY | BAK |
|---|---|---|
| Relative Strength Index (RSI) | 32.88 | 47.83 |
| Support Level | $25.71 | $3.34 |
| Resistance Level | $28.99 | $5.30 |
| Average True Range (ATR) | 0.75 | 0.42 |
| MACD | 0.22 | -0.08 |
| Stochastic Oscillator | 26.60 | 23.49 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.